Macrophage-Derived Exosomal Mir-155 Regulating Cardiomyocyte Pyroptosis and Hypertrophy in Uremic Cardiomyopathy

Bin Wang1, Ze-Mu Wang2, Jia-Ling Ji3

  • 1Institute of Nephrology, Zhong Da Hospital, Southeast University School of Medicine, Nanjing, Jiangsu, China.

Insights

Macrophage-derived exosomes carrying miR-155 promote uremic cardiomyopathy by targeting FoxO3a in heart cells. This leads to pyroptosis, cardiac hypertrophy, and fibrosis in uremic mice.

Area of Science:

  • Cardiovascular Biology
  • Molecular Biology
  • Exosome Biology

Background:

  • Uremic cardiomyopathy is characterized by cardiac hypertrophy and fibrosis.
  • Macrophage infiltration is increased in the uremic heart.
  • MicroRNAs (miRNAs) play crucial roles in cardiovascular diseases.

Purpose of the Study:

  • To investigate the role of exosomal miR-155 derived from macrophages in the pathogenesis of uremic cardiomyopathy.
  • To elucidate the molecular mechanism by which miR-155 affects cardiomyocytes in a uremic environment.

Main Methods:

  • Isolation and characterization of exosomes from macrophages.
  • In vivo studies using a mouse model of uremic cardiomyopathy.
  • Analysis of miR-155 expression, exosome release, and target gene regulation (FoxO3a).
  • Assessment of cardiomyocyte pyroptosis, cardiac hypertrophy, and fibrosis.

Main Results:

  • Macrophage-derived exosomes were found to contain increased levels of miR-155 in uremic conditions.
  • Exosomal miR-155 was transferred to cardiomyocytes, leading to translational repression of FoxO3a.
  • Targeting of FoxO3a by miR-155 promoted cardiomyocyte pyroptosis.
  • Macrophage-derived exosomal miR-155 exacerbated cardiac hypertrophy and fibrosis in uremic mice.

Conclusions:

  • Macrophage-derived exosomal miR-155 is a key mediator in the development of uremic cardiomyopathy.
  • The mechanism involves the targeting of FoxO3a, leading to pyroptosis and adverse cardiac remodeling.
  • Exosomes represent a potential therapeutic target for mitigating uremic cardiomyopathy.